Polyrizon Ltd. (PLRZ) News
Follow Polyrizon Ltd. (PLRZ) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
PLRZ - Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
PLRZ - Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
NEWS | Sep 22, 2026, 12:33 PM UTC
L
Polyrizon closes $4.0M registered direct offering and private placement
Polyrizon Ltd. has closed a $4.0 million registered direct offering and private placement.
EQUITY | Sep 04, 2026, 03:58 PM UTC
L
Polyrizon Ltd. announces $4.0 million registered direct offering
Polyrizon Ltd. announced a $4.0 million registered direct offering and private placement.
EQUITY | Sep 03, 2026, 12:50 PM UTC
L
Polyrizon completes fourth and fifth U.S. site contracts for NASARIX allergy study
Polyrizon said it has completed contracting for the fourth and fifth U.S. clinical sites for NASARIX™ first-in-human allergy study, completing all five U.S. site contracts for the trial.
GEOPOLITICS | Sep 02, 2026, 11:37 AM UTC
M
Polyrizon completes all five U.S. site contracts for NASARIX allergy study
Polyrizon (PLRZ) has completed all five U.S. site contracts for its NASARIX first-in-human allergy study.
EQUITY | Sep 02, 2026, 11:32 AM UTC
L
Polyrizon completes clinical site network for NASARIX study
Polyrizon says it has completed the clinical site network for its NASARIX study and is advancing toward patient enrollment, with no catalyst or timing details supplied.
EQUITY | Aug 20, 2026, 01:30 PM UTC
H
Polyrizon Reports NASARIX Biocompatibility Results, Supporting Advancement To First-In-Human Clinical Trial
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ )
EARNINGS | Jul 02, 2026, 08:13 PM UTC